HomeAll PostsCancer
AOA Dx Reaches Initial Validation of Novel Tumor Gangliosides as Diagnostic Markers for Early Detection of Ovarian Cancer
By Femtech Insider Cancer, News December 8, 2022
Ovarian cancer is the deadliest gynecological disease. Up to 95% of women with ovarian cancer have symptoms for many months and consult a doctor, but the average time to diagnosis is 9 months. An early stage diagnostic test may enable detection of malignancy helping to expedite workup and treatment plans. Detection of ovarian cancer at early-stages has a 5-year survival rate of…
Delphinus Adds $30M in Series D Funding to Take Its 3D Whole Breast Ultrasound Tomography System to Market
By Femtech Insider Breast Health, Cancer, Investment, News October 3, 2022
Forty percent of women in the U.S. have dense breast tissue, and they have a 4-6 times greater risk of developing breast cancer. Mammography alone misses about half the cancers in women with dense breasts, as dense tissue and cancer both appear white on mammogram images. Delphinus Medical Technology's SoftVue System is indicated for use as an adjunct to digital mammography in…
AOA Dx Adds $4.5M in Seed Funding to Develop the Next Generation of Its Ovarian Cancer Detection Technology
By Femtech Insider Cancer, Investment, News September 15, 2022
In June 2021 AOA Dx rasied $2.5M in seed funding after having participated in Y Combinator's 2021 summer cohort. Yesterday the company announced another funding round, which now brings total funding to $7M. Participants in the latest round include Avestria Ventures, AlleyCorp, The Helm, RH Capital, Olive Tree Capital, Tencent. The new funds will be used to further develop the next generation…
Singaporean Breast Cancer Diagnostics AI Startup FathomX Raises $2M in Pre-Series A Funding
By Femtech Insider Breast Health, Cancer, News September 5, 2022
Singapore-based digital health AI company FathomX, a spin-off company from the National University of Singapore (NUS) and National University Health System (NUHS), recently raised a Pre-series A fund of SGD $2.24M (ca. USD $2M) the lead up to Series A funding. Fathom X raised SGD$ 500K (ca. USD$ 350K) in a seed round in April 2021. Additionally, the I2Start Funding Program, a tripartite initiative to support company…
PINK!, A Digital Therapeutic for Breast Cancer Patients, Is Now Reimbursed as a Prescription Digital Health Product (DiGA) in Germany
By Femtech Insider Cancer, Digital Health, News July 12, 2022
The German government has added a new prescription digital therapeutic to its DiGA program: "PINK! Coach supports breast cancer patients in changing their lifestyle towards more exercise, healthier nutrition and mindfulness in accordance with the current guideline recommendations. Via coaching modules, patients receive pseudo-individualized information, practical tips, instructions and exercises in the areas of exercise, nutrition and mental health." The DiGa database is essentially a…
Sidekick Health and Eli Lilly Partner to Launch Digital Therapeutics for Breast Cancer Patients
By Femtech Insider Cancer, Digital Health, News, Partnership June 21, 2022
Sidekick Health and Eli Lilly are collaborating on an integrated digital therapeutics solution. The project marks the first phase of a relationship between Sidekick and Lilly, which starts with a digital therapeutic offering for patients battling breast cancer. The first phase will consist of the integrated digital therapeutic offering rollout in Germany. Reykjavik, Iceland-based Sidekick said the further expansion of its portfolio…
Celmatix Reaches a Key Preclinical Milestone in Its Premature Menopause Prevention Drug Program
By Femtech Insider Biotech, Cancer, Menopause, News May 16, 2022
We last spoke about Celmatix in January, when the company announced that a novel PCOS target identified as part of its five-year, multi-target alliance with Evotec has progressed into hit-identification. Now the company is back with more promising news and this time it's about premature menopause. According to a release Celmatix has identified of a novel AMHR2 agonist compound that has demonstrated…
Vara Teams Up with Greek Healthcare Provider MITERA to Launch Decentralized Breast Cancer Screening Centers
By Femtech Insider Cancer, News, Partnership March 28, 2022
There are 700,000 deaths from breast cancer every year. In Greece breast cancer is the most common cancer among women and the third most common cancer in the Greek population representing 12% of all cases in 2020. Vara, the startup known for its AI-powered breast cancer screening and data management platform, has now entered a new partnership with MITERA, the largest private…